Autoimmunity BioSolutions is a preclinical-stage biotech focused on immuno-corrective therapies for autoimmune disease, and this weekly recap reviews its latest financing and R&D plans. The company reported closing a $1 million seed extension round, bringing total seed capital to $3.1 million.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Existing investors EOS BioInnovation, Independent Capital and Elmstead Partners all participated, alongside new family office investor NewTech Investment Holdings. The expanded syndicate broadens Autoimmunity BioSolutions’ early backer base and signals continued confidence in its strategy.
Management plans to use the new capital to fund animal model studies and patient biosample analyses in rheumatoid arthritis, its lead indication. These studies are intended to generate proof-of-concept and translational data that can support future, larger fundraising rounds or potential partnerships.
The company is advancing a genetically guided, immuno-corrective platform that targets elevated soluble IL7 receptor, or sIL7R. Autoimmunity BioSolutions has identified a common genetic variant, present in roughly half the population, that drives a two- to three-fold increase in sIL7R levels.
Elevated sIL7R has been associated with more severe disease, faster progression and weaker response to standard-of-care therapies in several autoimmune conditions. These include rheumatoid arthritis, lupus nephritis and type 1 diabetes, positioning the company to address a sizable subset of refractory patients.
While the fresh funding remains focused on preclinical and exploratory work, it potentially extends the company’s runway through key validation milestones. Demonstrating robust animal and human biospecimen data could improve Autoimmunity BioSolutions’ standing with institutional investors and strategic immunology players.
At the same time, the update underscores that the company is still far from commercialization and will likely require additional capital before any revenue prospects emerge. Overall, the week marked a constructive step for Autoimmunity BioSolutions as it strengthened its balance sheet and advanced its genetically targeted autoimmune platform.